Literature DB >> 29707321

Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer.

Jun Zhao1, Jiagen Li1, Ning Li1, Shugeng Gao1.   

Abstract

BACKGROUND: Lymph node metastasis is critical for the prognosis of non-small cell lung cancer (NSCLC) patients, and understanding of the pattern of lymph node metastasis is key to the treatment. We aim to investigate the N2 NSCLC patients without N1 lymph node involvement.
METHODS: From 1999 to 2005, a total of 803 patients with pN2 NSCLC were enrolled in this study. Among them, 137 pN2 patients with no metastasis at the hilar (N1) lymph nodes [skip (+) group] were compared with the other 666 patients [skip (-) group].
RESULTS: The percentage of male, smoker and squamous cell carcinoma patients were significantly higher in the skip (+) group, (83.21% vs. 64.11%, P<0.001; 76.64% vs. 53.60%, P<0.001; 50.36% vs. 37.54%, P=0.007, respectively). Also, the primary tumor of skip (+) group patients were significantly more often located in the right upper and middle lobe (43.07% vs. 23.42%, 10.95% vs. 4.05%, P=0.001), and metastasis more frequently involved one lymph node station (75.18% vs. 49.55%, P<0.001). There was no significant difference in the number of total and N2 lymph node dissected. The postoperative survival of patients in both groups were also similar (P=0.379).
CONCLUSIONS: Skipping mediastinal lymph node metastasis happens in about 17% of NSCLC patients with mediastinal lymph nodes metastasis but it is not a prognostic factor.

Entities:  

Keywords:  Non-small cell lung cancer; lymph node metastasis; prognosis; skip

Year:  2018        PMID: 29707321      PMCID: PMC5906225          DOI: 10.21037/jtd.2018.01.176

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  22 in total

1.  Analysis of risk factors for skip lymphatic metastasis and their prognostic value in operated N2 non-small-cell lung carcinoma.

Authors:  L Benoit; A Anusca; P Ortega-Deballon; N Cheynel; A Bernard; J P Favre
Journal:  Eur J Surg Oncol       Date:  2006-04-18       Impact factor: 4.424

2.  Demonstration of the skip metastasis pathway for N2 non-small cell lung cancer.

Authors:  Hiromitsu Takizawa; Shoji Sakiyama; Mitsuhiro Tsuboi; Akira Tangoku
Journal:  J Thorac Cardiovasc Surg       Date:  2014-01-15       Impact factor: 5.209

3.  Role of skip metastasis to mediastinal lymph nodes in non-small cell lung cancer.

Authors:  Klaus L Prenzel; Stefan P Mönig; Jan M Sinning; Stefan E Baldus; Christian A Gutschow; Guido Grass; Paul M Schneider; Arnulf H Hölscher
Journal:  J Surg Oncol       Date:  2003-04       Impact factor: 3.454

4.  Five-year survivors with resected pN2 nonsmall cell lung carcinoma.

Authors:  M Sagawa; A Sakurada; S Fujimura; M Sato; S Takahashi; K Usuda; C Endo; H Aikawa; T Kondo; Y Saito
Journal:  Cancer       Date:  1999-02-15       Impact factor: 6.860

5.  Case-Control Study: Smoking History Affects the Production of Tumor Antigen-Specific Antibodies NY-ESO-1 in Patients with Lung Cancer in Comparison with Cancer Disease-Free Group.

Authors:  Dagmar Myšíková; Irena Adkins; Nad'a Hradilová; Ondřej Palata; Jan Šimonek; Jiří Pozniak; Jan Kolařík; Anna Skallová-Fialová; Radek Špíšek; Robert Lischke
Journal:  J Thorac Oncol       Date:  2016-10-25       Impact factor: 15.609

6.  Mode of spread in the early phase of lymphatic metastasis in non-small-cell lung cancer: significance of nodal micrometastasis.

Authors:  J R Izbicki; B Passlick; S B Hosch; B Kubuschock; C Schneider; C Busch; W T Knoefel; O Thetter; K Pantel
Journal:  J Thorac Cardiovasc Surg       Date:  1996-09       Impact factor: 5.209

7.  Skip mediastinal lymph node metastasis and lung cancer: a particular N2 subgroup with a better prognosis.

Authors:  Marc Riquet; Jalal Assouad; Patrick Bagan; Christophe Foucault; Françoise Le Pimpec Barthes; Antoine Dujon; Claire Danel
Journal:  Ann Thorac Surg       Date:  2005-01       Impact factor: 4.330

8.  Skip metastasis in nonsmall cell lung carcinoma: predictive markers and isolated tumor cells in N1 lymph nodes.

Authors:  Klaus L Prenzel; Stephan E Baldus; Stefan P Mönig; Daniela Tack; Jan M Sinning; Christian A Gutschow; Guido Grass; Paul M Schneider; Hans P Dienes; Arnulf H Hölscher
Journal:  Cancer       Date:  2004-05-01       Impact factor: 6.860

9.  Skip mediastinal nodal metastases in the IIIa/N2 non-small cell lung cancer.

Authors:  Nenad Ilic; Ante Petricevic; Dragan Arar; Slavica Kotarac; Josip Banovic; Nives Frleta Ilic; Andro Tripkovic; Leo Grandic
Journal:  J Thorac Oncol       Date:  2007-11       Impact factor: 15.609

10.  Skip metastases: analysis of their clinical significance and prognosis in the IIIA stage of non-small cell lung cancer.

Authors:  P Misthos; E Sepsas; K Athanassiadi; S Kakaris; I Skottis
Journal:  Eur J Cardiothorac Surg       Date:  2004-04       Impact factor: 4.191

View more
  2 in total

1.  Slug and Vimentin downregulation at the metastatic site is associated with Skip-N2 metastasis of lung adenocarcinoma.

Authors:  Yasemin Saygideger; Alper Avci; Emine Bagir; Burcu Saygıdeğer Demir; Aycan Sezan; Mucahit Ekici; Oya Baydar; Özgür Cem Erkin
Journal:  Discov Oncol       Date:  2022-01-22

2.  Correlation between Skip N2 Metastases and SUVmax, Long Diameter of Tumor, and Ki67 Expression in Patients with Non-Small-Cell Lung Cancer.

Authors:  Wang Jian; Peng Ming-Ya; Xu Long-Bao; Zhao Jun; Shao Guo-Qiang
Journal:  Biomed Res Int       Date:  2020-04-25       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.